<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106938</url>
  </required_header>
  <id_info>
    <org_study_id>AVD-640-0052</org_study_id>
    <nct_id>NCT00106938</nct_id>
  </id_info>
  <brief_title>Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)</brief_title>
  <acronym>ACT I</acronym>
  <official_title>Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <brief_summary>
    <textblock>
      The study is being conducted to demonstrate the non-inferiority of carotid artery stenting
      (CAS) using the Emboshield® Embolic Protection System with the Xact® Carotid Stent System to
      carotid endarterectomy (CEA) for the treatment of asymptomatic extracranial carotid
      atherosclerotic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization for ACT 1 employs a 3:1 ratio of CAS versus CEA. A lead-in phase of up to 400
      carotid stent subjects will provide investigators experience with the study devices prior to
      pivotal enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision and not a result of any patient or product safety issues.
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Death, Stroke (Ipsilateral or Contralateral; Major or Minor) and Myocardial Infarction (DSMI) Through 30 Days Post-procedure, Plus Ipsilateral Stroke 31 to 365 Days.</measure>
    <time_frame>0 to 365 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Device Success: Xact Carotid Stent</measure>
    <time_frame>On day 0 after index procedure</time_frame>
    <description>Defined as attainment of final residual diameter stenosis of &lt; 50% by Qualitative Comparative Analysis (QCA) (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Device Success: Embolic Protection Device System</measure>
    <time_frame>On day 0 after index procedure</time_frame>
    <description>Defined as successful deployment and retrieval of the filter in the absence of angiographic distal embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>0 to 30 days post procedure</time_frame>
    <description>Procedural success is defined as the attainment of target lesion final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) using any procedural method and freedom of Major Adverse Event at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Morbidity Measure</measure>
    <time_frame>0 to 30 Days Post-procedure</time_frame>
    <description>A pre-specified composite Morbidity Measure (CMM) of cranial and peripheral nerve injury, vascular injury, non-cerebral bleeding, wound complications related to the neck incision or femoral puncture site, and other complications (anesthetic) at 30 days post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization(CI-TLR)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>Freedom from CI-TLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 365 days</time_frame>
    <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 730 days</time_frame>
    <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 1095 days</time_frame>
    <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 1460 days</time_frame>
    <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 1825 days</time_frame>
    <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 365 days</time_frame>
    <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 730 days</time_frame>
    <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 1095 days</time_frame>
    <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 1460 days</time_frame>
    <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 1825 days</time_frame>
    <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 1095 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 1460 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 1825 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All Stroke</measure>
    <time_frame>0 to 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All Stroke</measure>
    <time_frame>0 to 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All Stroke</measure>
    <time_frame>0 to 1095 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All Stroke</measure>
    <time_frame>0 to 1460 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All Stroke</measure>
    <time_frame>0 to 1825 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (Non-Hierarchical)</measure>
    <time_frame>≤ 30 Days Post Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Stroke (Non-Hierarchical)</measure>
    <time_frame>≤ 30 Days Post Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (Non-Hierarchical)</measure>
    <time_frame>≤ 30 Days Post Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, Stroke or Myocardial Infarction (MI) (Hierarchical)</measure>
    <time_frame>≤ 30 Days Post Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or Stroke (Hierarchical)</measure>
    <time_frame>≤ 30 Days Post Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or Major Stroke (Hierarchical)</measure>
    <time_frame>≤ 30 Days Post Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Death, Stroke and MI Within 30 Days and Ipsilateral Stroke From 31 Days to 5 Years</measure>
    <time_frame>0 to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1663</enrollment>
  <condition>Carotid Artery Disease</condition>
  <condition>Carotid Stenosis</condition>
  <condition>Stroke</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carotid artery stenting with filter (interventional)</intervention_name>
    <description>Carotid artery stenting with filter (interventional)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carotid artery endarterectomy (surgical)</intervention_name>
    <description>Carotid artery endarterectomy (surgical)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must be &gt; 18 and &lt; 80 years of age.

          2. Female subjects of child bearing potential must have a documented negative pregnancy
             test within 30 days prior to the study procedure.

          3. Subject must be asymptomatic, defined as no stroke or Transient Ischemic Attack
             [(TIA);(hemispheric or ocular)] within the 180 days prior to the procedure. Subjects
             who have experienced these neurological symptoms prior to the 180 day pre-procedure
             window will be eligible for enrollment. An independent study neurologist or
             independent study neurosurgeon must confirm the subject's neurological status.

          4. Subjects taking warfarin may be included if their dosage is reduced before the
             procedure to result in an International Normalized Ratio (INR) of 1.5 or less.
             Warfarin may be restarted after the procedure.

          5. The subject must sign a written informed consent prior to the procedure, using a form
             that is approved by the local institutional review board (IRB).

          6. The subject must agree to return for all required follow-up visits.

          7. Subject has a discrete lesion located in the internal carotid artery (ICA); the
             contiguous common carotid artery (CCA) may be involved.

          8. Carotid stenosis ≥ 70% and ≤ 99% by carotid ultrasound or ≥ 70% and ≤ 99% stenosis
             (visual estimate) by angiography, without significant (&gt; 60% by ultrasound or
             angiography) ICA/CCA contralateral stenosis.

          9. Target ICA vessel diameter must be visually estimated to be:

             &gt; 2.5 mm and &lt; 7.0 for the Emboshield Pro or for the Emboshield NAV6, &gt; 2.8 mm and &lt;
             6.2 for the Emboshield Gen 3 And &gt; 4.0 mm and &lt; 9.0 mm for the Xact stent treatment
             segment. An untreated contralateral ICA may be used for visual estimation when a
             highly stenosed lesion makes measurement of the target vessel inaccurate.

         10. Based on the subject's anatomy, the Investigator should expect to successfully deliver
             the stent to the target lesion (absence of extreme tortuosity, etc.).

         11. De novo target lesion that can be treated with a single stent.

        Exclusion Criteria:

        Each potential subject must be screened to ensure that they do not meet any of the
        following exclusion criteria. This screening is to be based on known medical history and
        data available at the time of eligibility determination and enrollment.

          1. Subject is symptomatic and has had a stroke or exhibited TIA (hemispheric or ocular)
             within 180 days prior to randomization, which has been confirmed by an independent
             study neurologist or independent study neurosurgeon.

          2. Subject is participating in another drug or device trial (IND or IDE) that has not
             completed the primary endpoint or that may potentially confound the results of this
             trial. Subject may be enrolled only once in this trial and may not participate in any
             other clinical trial during a 1-year period post-index procedure.

          3. Subject has inability to understand and cooperate with study procedures or provide
             informed consent.

          4. Subject has had an intracranial hemorrhage or hemorrhagic stroke within 1-year prior
             the index procedure.

          5. Subject has dementia or has a neurological illness that may confound the neurological
             evaluation.

          6. Subject has had a known untoward reaction to anesthesia or contrast media not able to
             be overcome by pre-treatment with medications.

          7. Subject has history of intolerance or allergic reaction to any of the study
             medications including aspirin, Clopidogrel bisulfate (Plavix®) or Ticlopidine
             (Ticlid®), heparin or Bivalirudin (Angiomax™). Subjects must be able to tolerate a
             combination of aspirin and Clopidogrel/Ticlopidine.

          8. Subject has Hemoglobin (Hgb) less than 10 gm/dL, platelet count &lt;100,000/mm3 or
             &gt;500,000/mm3, or known heparin associated thrombocytopenia.

          9. Subject has an active bleeding diathesis or coagulopathy, or will refuse blood
             transfusions.

         10. Subject has had a GI bleed that would interfere with antiplatelet therapy.

         11. Subject has known cardiac sources of emboli, including paroxysmal or sustained atrial
             fibrillation (treated or untreated).

         12. Subject has had an myocardial infarction (MI) within the previous 30 days.

         13. Subject has any condition that limits their anticipated survival to less than 3 years.

         14. Subject is a high risk surgical candidate defined as the presence of any one or more
             of a following medical conditions:

               1. Two or more proximal diseased coronary arteries of &gt; 70% stenosis that have not
                  or cannot be revascularized or &lt; 30 days since revascularization.

               2. Ejection fraction &lt; 30% or New York Heart Association (NYHA) heart failure
                  functional class 3 or higher.

               3. Unstable angina, defined as angina at rest with ECG changes.

               4. On a list for major organ transplant or is being evaluated for such.

               5. Known history of respiratory insufficiency, forced expiratory volume (FEV1) &lt; 30%
                  (predicted).

               6. Chronic renal insufficiency (serum creatinine &gt;2.5 mg/dL).

               7. Uncontrolled diabetes defined as fasting glucose &gt; 400 mg/dL.

               8. Concurrent requirement for any invasive procedure 30 days pre- or post-procedure.

               9. Age ≥ 80 years.

         15. Subject may be considered a non-surgical candidate for CEA as a result of one or more
             anatomic conditions or features which preclude normal surgical access or a high
             surgical risk because of the presence of any one or more anatomic conditions that
             present an increased potential for adverse events. These subjects are not eligible for
             enrollment.

               1. Subject has had radiation treatment to the neck.

               2. Subject has had a radical neck dissection.

               3. Surgically inaccessible lesions (i.e., lesions extending above the level of C2).

               4. Spinal immobility - inability to flex neck beyond neutral or kyphotic deformity.

               5. Presence of carotid artery dissection, aneurysm, pseudoaneurysm, arteritis or
                  fibromuscular dysplasia (FMD) in the target vessel.

               6. Hemodynamically significant (&gt;60%) stenosis of the right or left common carotid
                  artery (LCCA/RCCA) below the clavicle.

               7. Presence of tracheostomy stoma.

               8. Contralateral laryngeal nerve paralysis.

               9. Previous carotid endarterectomy, extracranial-intracranial or carotid subclavian
                  bypass procedure ipsilateral to the carotid stenosis.

              10. Severe hypertension (defined as blood pressure &gt; Systolic of 180 mm Hg and/or a
                  diastolic of 110 mm Hg) not adequately controlled by anti-hypertensive therapy at
                  the time of study entry.

         16. Severe vascular disease including tortuosity and/or occlusive disease that would
             preclude the safe introduction of a guiding catheter/sheath, cerebral protection
             device, balloon catheter, stent delivery system or stent placement. Severe tortuosity
             is defined as 2 or more &gt;90 degree bend points within 3cm of the target stenosis. One
             of these bends will be considered to be present if the ICA branches from the CCA at a
             90 degree angle. This includes aortic arch anatomy that is unacceptable for carotid
             stent placement.

         17. Intraluminal filling defect thought to represent thrombus.

         18. Excessive calcification: defined as fluoroscopic evidence of calcium that extends
             circumferentially around the target lesion and includes the majority of the
             atherosclerotic plaque.

         19. Occlusion (TIMI 0 flow), or string sign of the ipsilateral common or internal carotid
             artery.

         20. The target lesion requires treatment with a device other than percutaneous
             transluminal angioplasty (PTA) prior to stent placement.

         21. Significant (&gt; 60%) stenosis proximal or distal to the target lesion that might
             require revascularization or impede run off.

         22. Presence of a previously placed intravascular stent in the ipsilateral carotid
             distribution.

         23. Cerebral aneurysm (symptomatic or &gt; 10 mm) or arteriovenous malformation (AVM) of the
             cerebral vasculature.

         24. Bilateral carotid stenosis (ICA/CCA contralateral stenosis &gt; 60% by ultrasound or
             angiography).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Matsumura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Rosenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's Hospital-Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fogarty Clinical Research Inc./El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Foundation Hospital-San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac and Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Permanente Medical Group - Kaiser</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital and Memorial Medical Center/ Prairie Heart Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital/Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Regional Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millard Fillmore Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester-Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Health and Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Stroke Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Valley Health System</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrisburg Hospital / Pinnacle Health</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Physicians Division of Vascular Surgery/Shadyside Medical</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Washington</city>
        <state>Pennsylvania</state>
        <zip>15301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Medical Center/Berks Cardiologists</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital-SC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Heart Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Center/Methodist Germantown Hospital</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical West/Turkey Creek Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Medical Center/Seton Heart Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Veteran's Administration Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake General Hospital/Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital / Virginia Cardiovascular Specilists</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center - Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2005</study_first_submitted>
  <study_first_submitted_qc>April 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2005</study_first_posted>
  <results_first_submitted>April 2, 2014</results_first_submitted>
  <results_first_submitted_qc>October 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2014</results_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carotid stenting</keyword>
  <keyword>Carotid endarterectomy</keyword>
  <keyword>Carotid artery disease with severe narrowing of the artery</keyword>
  <keyword>Stroke prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Asymptomatic subjects with extracranial internal carotid stenosis which was ≥70% &amp; ≤99% by duplex ultrasound or ≥70% &amp; ≤99% by angiography (visual estimate) with or without involvement of the contiguous common carotid artery, who could undergo carotid artery stenting/carotid endarterectomy and all follow-ups, were recruited starting from April 2005</recruitment_details>
      <pre_assignment_details>1453 patients were randomized to support the primary analysis; an additional 210 lead-in subjects were enrolled to allow investigators to gain experience with the study devices prior to randomizing subjects and were not part of the primary analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CAS Group</title>
          <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
        <group group_id="P2">
          <title>CEA Group</title>
          <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1089"/>
                <participants group_id="P2" count="364"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="913"/>
                <participants group_id="P2" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CAS Group</title>
          <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
        <group group_id="B2">
          <title>CEA Group</title>
          <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1089"/>
            <count group_id="B2" value="364"/>
            <count group_id="B3" value="1453"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="428"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="764"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="1025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="7.0"/>
                    <measurement group_id="B2" value="67.9" spread="6.9"/>
                    <measurement group_id="B3" value="67.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="423"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="580"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="666"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="985"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="1312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1089"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="1453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite of Death, Stroke (Ipsilateral or Contralateral; Major or Minor) and Myocardial Infarction (DSMI) Through 30 Days Post-procedure, Plus Ipsilateral Stroke 31 to 365 Days.</title>
        <time_frame>0 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Death, Stroke (Ipsilateral or Contralateral; Major or Minor) and Myocardial Infarction (DSMI) Through 30 Days Post-procedure, Plus Ipsilateral Stroke 31 to 365 Days.</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Device Success: Xact Carotid Stent</title>
        <description>Defined as attainment of final residual diameter stenosis of &lt; 50% by Qualitative Comparative Analysis (QCA) (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
        <time_frame>On day 0 after index procedure</time_frame>
        <population>Device success is per device basis including the attempted devices only, including the attempted Carotid Artery Stenting (CAS) device only.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Device Success: Xact Carotid Stent</title>
          <description>Defined as attainment of final residual diameter stenosis of &lt; 50% by Qualitative Comparative Analysis (QCA) (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
          <population>Device success is per device basis including the attempted devices only, including the attempted Carotid Artery Stenting (CAS) device only.</population>
          <units>percentage of devices</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>devices</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1025"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" lower_limit="95.6" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Device Success: Embolic Protection Device System</title>
        <description>Defined as successful deployment and retrieval of the filter in the absence of angiographic distal embolization.</description>
        <time_frame>On day 0 after index procedure</time_frame>
        <population>Device success is per device basis including the attempted devices only, including the attempted Carotid Artery Stenting (CAS) device only.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Device Success: Embolic Protection Device System</title>
          <description>Defined as successful deployment and retrieval of the filter in the absence of angiographic distal embolization.</description>
          <population>Device success is per device basis including the attempted devices only, including the attempted Carotid Artery Stenting (CAS) device only.</population>
          <units>Percentage of devices</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Devices</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1045"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="96.7" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success is defined as the attainment of target lesion final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) using any procedural method and freedom of Major Adverse Event at 30 days.</description>
        <time_frame>0 to 30 days post procedure</time_frame>
        <population>The analysis population is Procedure success is per subject basis including the attempted CAS (carotid artery stenting) procedure only. CEA group is not part of analysis population for procedure success.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success is defined as the attainment of target lesion final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) using any procedural method and freedom of Major Adverse Event at 30 days.</description>
          <population>The analysis population is Procedure success is per subject basis including the attempted CAS (carotid artery stenting) procedure only. CEA group is not part of analysis population for procedure success.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Morbidity Measure</title>
        <description>A pre-specified composite Morbidity Measure (CMM) of cranial and peripheral nerve injury, vascular injury, non-cerebral bleeding, wound complications related to the neck incision or femoral puncture site, and other complications (anesthetic) at 30 days post-procedure.</description>
        <time_frame>0 to 30 Days Post-procedure</time_frame>
        <population>Intent-to-Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Morbidity Measure</title>
          <description>A pre-specified composite Morbidity Measure (CMM) of cranial and peripheral nerve injury, vascular injury, non-cerebral bleeding, wound complications related to the neck incision or femoral puncture site, and other complications (anesthetic) at 30 days post-procedure.</description>
          <population>Intent-to-Treat (ITT) population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite morbidity measure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cranial nerve injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral nerve injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cerebral bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CEA wound or access artery wound</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization(CI-TLR)</title>
        <description>Freedom from CI-TLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
        <time_frame>0 to 180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization(CI-TLR)</title>
          <description>Freedom from CI-TLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8"/>
                    <measurement group_id="O2" value="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
        <time_frame>0 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
        <time_frame>0 to 730 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
        <time_frame>0 to 1095 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
        <time_frame>0 to 1460 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
        <time_frame>0 to 1825 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <description>Freedom from CITLR was defined as freedom from reintervention for ≥ 50% restenosis in recently symptomatic patients and ≥ 80% restenosis in asymptomatic patients.</description>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
        <time_frame>31 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
        <time_frame>31 to 730 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0"/>
                    <measurement group_id="O2" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
        <time_frame>31 to 1095 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
        <time_frame>31 to 1460 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8"/>
                    <measurement group_id="O2" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
        <time_frame>31 to 1825 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <description>Ipsilateral stroke was defined as stroke in the vascular distribution of the study carotid artery. If a subject experienced a bilateral stroke it was counted as an ipsilateral stroke for analysis purposes.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8"/>
                    <measurement group_id="O2" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 730 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2"/>
                    <measurement group_id="O2" value="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 1095 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 1460 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                    <measurement group_id="O2" value="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 1825 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1"/>
                    <measurement group_id="O2" value="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All Stroke</title>
        <time_frame>0 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5"/>
                    <measurement group_id="O2" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All Stroke</title>
        <time_frame>0 to 730 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8"/>
                    <measurement group_id="O2" value="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All Stroke</title>
        <time_frame>0 to 1095 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5"/>
                    <measurement group_id="O2" value="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All Stroke</title>
        <time_frame>0 to 1460 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All Stroke</title>
        <time_frame>0 to 1825 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death (Non-Hierarchical)</title>
        <time_frame>≤ 30 Days Post Index Procedure</time_frame>
        <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Death (Non-Hierarchical)</title>
          <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1072"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Stroke (Non-Hierarchical)</title>
        <time_frame>≤ 30 Days Post Index Procedure</time_frame>
        <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>All Stroke (Non-Hierarchical)</title>
          <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1072"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.9" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.5" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) (Non-Hierarchical)</title>
        <time_frame>≤ 30 Days Post Index Procedure</time_frame>
        <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) (Non-Hierarchical)</title>
          <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1072"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.2" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.2" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death, Stroke or Myocardial Infarction (MI) (Hierarchical)</title>
        <time_frame>≤ 30 Days Post Index Procedure</time_frame>
        <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Death, Stroke or Myocardial Infarction (MI) (Hierarchical)</title>
          <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1072"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.3" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.2" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death or Stroke (Hierarchical)</title>
        <time_frame>≤ 30 Days Post Index Procedure</time_frame>
        <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Stroke (Hierarchical)</title>
          <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1072"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.0" upper_limit="4.1"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.6" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death or Major Stroke (Hierarchical)</title>
        <time_frame>≤ 30 Days Post Index Procedure</time_frame>
        <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Major Stroke (Hierarchical)</title>
          <population>Analysis population Includes only the most serious event for each subject and includes only each subject's first occurrence of the event. Subjects who did not complete 30 day follow-up and did not have any death, stroke or MI events are excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1072"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Death, Stroke and MI Within 30 Days and Ipsilateral Stroke From 31 Days to 5 Years</title>
        <time_frame>0 to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Death, Stroke and MI Within 30 Days and Ipsilateral Stroke From 31 Days to 5 Years</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6"/>
                    <measurement group_id="O2" value="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CAS Group</title>
          <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
        <group group_id="E2">
          <title>CEA Group</title>
          <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="376" subjects_at_risk="1089"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1089"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1089"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal lab test</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="1089"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="70" subjects_affected="57" subjects_at_risk="1089"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Structural heart disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="1089"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Miscellaneous</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1089"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="1089"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="1089"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Vessel trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="45" subjects_affected="41" subjects_at_risk="1089"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="1089"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Cranial nerve palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hyperperfusion syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Neurologic other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1089"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>TIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1089"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Ipsilateral major</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Ipsilateral minor</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="1089"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Non-ipsilateral major</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Non-ipsilateral minor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental health related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="1089"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anesthesia/Procedural medication related</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1089"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Cranial nerve injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Heparin induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1089"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="1089"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Vessel trauma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1089"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Abdominal Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1089"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Contralateral stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1089"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="56" subjects_affected="41" subjects_at_risk="1089"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Renal artery disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1089"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1089"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Target lesion restenosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1089"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="635" subjects_at_risk="1089"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="115" subjects_affected="93" subjects_at_risk="1089"/>
                <counts group_id="E2" events="41" subjects_affected="33" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="140" subjects_affected="107" subjects_at_risk="1089"/>
                <counts group_id="E2" events="47" subjects_affected="40" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="92" subjects_affected="81" subjects_at_risk="1089"/>
                <counts group_id="E2" events="31" subjects_affected="23" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anesthesia/Procedural medication related</sub_title>
                <counts group_id="E1" events="70" subjects_affected="65" subjects_at_risk="1089"/>
                <counts group_id="E2" events="55" subjects_affected="51" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="148" subjects_affected="140" subjects_at_risk="1089"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Cranial nerve injury</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="1089"/>
                <counts group_id="E2" events="51" subjects_affected="48" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="74" subjects_affected="73" subjects_at_risk="1089"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="1089"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="268" subjects_affected="252" subjects_at_risk="1089"/>
                <counts group_id="E2" events="36" subjects_affected="35" subjects_at_risk="364"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="60" subjects_affected="56" subjects_at_risk="1089"/>
                <counts group_id="E2" events="66" subjects_affected="64" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="58" subjects_affected="51" subjects_at_risk="1089"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="211" subjects_affected="173" subjects_at_risk="1089"/>
                <counts group_id="E2" events="36" subjects_affected="28" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="66" subjects_affected="56" subjects_at_risk="1089"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer M Jones-McMeans, PhD (Associate Director Clinical Research)</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-1459</phone>
      <email>jennifer.jones@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

